[An adapted model of cost-effectiveness analysis for the drug entecavir vs pegylated interferon in Venezuela].
In order to compare the cost and to find the cost-effectiveness ratio of 0.5 mg/day entecavir versus pegylated interferon in the suppression of the viral replication and the quality of life of chronic hepatitis B patients based on a previously developed economic evaluation by Spackman y Veenstra, we performed, previous data transferability analysis, an adaptation of the model to the Venezuelan reality. To adapt the economic evaluation, we assumed the probabilities of transition between states, in accordance with the effectiveness reported in the original evaluation. The hypothetical cohort was based on the characteristics of patients in recent clinical trials. The model results included the cost of each treatment alternative, entecavir and pegylated interferon, as well as quality adjusted life years (QALYs) gained. Entecavir 0.5 mgprovides 18,25 QALYs compared with 18,12 QALYs provided by pegylated interferon. The cost per QALY was 5.257 BsF for entecavir compared with pegylated interferon whose cost ranges 6.716 y 7.358 BsF per QALY CONCLUSIONS: Entecavir 0.5 mg provides a greater amount of QALYs and a better cost-effectiveness ratio than pegylated interferon showing extended dominancy over this.